Brumm Joshua T
Visual SEC Form 4 history across 2 companies, 13 transactions and 2 filings.
Open-market buy performance
90-day forward return on this insider's open-market purchases
We compute this from each buy's stock performance 90 days after the transaction. The price history is still being populated for this insider's their open-market buys, so the average and median will appear here once the daily price refresh has covered the relevant trading days.
Monthly open-market activity
Reported purchase and sale transaction counts
Net value flow
Buys minus sells
Transaction texture
Ownership and ticket size
Filing-only signals
Deterministic matches in this insider's history
Latest Form 4 facts
Quick context from source filings
sale at CRESCENT BIOPHARMA, INC. on Sep 18, 2026 valued at $130,956.
Review SEC filingNo open-market insider purchase is available.
Associated companies
Visual map of known reporting history
Latest insider transactions
Form 4 filings from available history. Click any column to sort; click it again to flip the order.
| ID | Ticker | Insider | Role | Type | Shares | Value | Code | Filed | Trans date |
|---|---|---|---|---|---|---|---|---|---|
| #197813 | DYN | Brumm Joshua T | CEOPRES | sale10b5-1 | 19.7k | -$37.6M | S | 01/04/2024 | 01/03/2024 |
| #197812 | DYN | Brumm Joshua T | CEOPRES | sale10b5-1 | 15.3k | -$28.2M | S | 01/04/2024 | 01/03/2024 |
| #197810 | DYN | Brumm Joshua T | CEOPRES | exercise10b5-1 | 51.1k | $5.27M | M | 01/04/2024 | 01/03/2024 |
Brumm Joshua T Insider Activity FAQ
SEC Form 4 context
Who is Brumm Joshua T?
Brumm Joshua T is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001528826.
Which companies has Brumm Joshua T reported transactions for?
CRESCENT BIOPHARMA, INC., Dyne Therapeutics, Inc.
When was Brumm Joshua T's latest insider buy?
No open-market insider purchase is available for this period.
When was Brumm Joshua T's latest insider sale?
sale at CRESCENT BIOPHARMA, INC. on Sep 18, 2026 valued at $130,956.
Where can I see the original SEC filings?
Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.
Are performance metrics included?
This version does not calculate win rates, forward returns, benchmark-adjusted returns, or high-conviction scores.